Cancer Family
Leukemia
CI-CAN-00000215Explore in graph →
HematologicTop-level1,769 active trials42 approved drugs708 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000215Explore in graph →
Clinical trials
8,437 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,348)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02971397 | Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 1 | 40 | Wake Forest University Health SciencesOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT01343173 | Multicenter Trial Estimating the Persistence of Molecular Remission in Chronic Myeloid Leukaemia in Long Term After Stopping Imatinib(STIM 2) | completed | N/A | 220 | University Hospital, BordeauxOTHER | 1 | Jul 31, 2026 |
| clinicaltrials |
| NCT01503632 | Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission | completed | Phase 3 | 570 | Children's Oncology GroupNETWORK | 2 | Jul 31, 2026 | clinicaltrials |
| NCT00400946 | 05-001: Treatment of Acute Lymphoblastic Leukemia in Children | completed | Phase 3 | 800 | Dana-Farber Cancer InstituteOTHER | 2 | Jul 30, 2026 | clinicaltrials |
| NCT01134575 | CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL) | completed | Phase 2 | 90 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT04975555 | Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy | completed | Phase 2 | 20 | University of Alabama at BirminghamOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT03672539 | Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome | completed | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT03374332 | Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 11 | Brown UniversityOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT03836209 | Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia | completed | Phase 2 | 181 | PrECOG, LLC.OTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT02337829 | Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL | completed | Phase 2 | 48 | Acerta Pharma BVINDUSTRY | 1 | Jul 21, 2026 | clinicaltrials |
| NCT01750567 | A Pilot Study of Metformin Therapy in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL) and Untreated CLL | completed | Phase 2 | 37 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT03455504 | Venetoclax Add in Combination With Fludarabine, Cyratabine and Idarubicine in Induction for Acute Myelid Leukemia(V-FIRST) | completed | Phase 2 | 124 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT05090956 | Developpement of 3T MRI Protocol((MISAP)) | completed | N/A | 230 | Institut National de la Santé Et de la Recherche Médicale, FranceOTHER_GOV | 1 | Jul 20, 2026 | clinicaltrials |
| NCT03480360 | Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression | completed | Phase 3 | 21 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT04746950 | ALICIA (Acalabrutinib in CLL Therapy)(ALICIA) | completed | — | 90 | AstraZenecaINDUSTRY | 1 | Jul 17, 2026 | clinicaltrials |
| NCT05024045 | Study of Oral LOXO-338 in Patients With Advanced Blood Cancers | completed | Phase 1 | 27 | Eli Lilly and CompanyINDUSTRY | 4 | Jul 17, 2026 | clinicaltrials |
| NCT04846855 | Regional Anesthesia for Totally Awake Upper Limb Surgery in PEDiatric Population(RATAPED) | completed | Phase 4 | 100 | GCS Ramsay Santé pour l'Enseignement et la RechercheOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06795139 | Pilot of a Trial Enrollment Diversity Dashboard(TEDD) | completed | N/A | 12 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06035757 | The Occurrence of Emergence Agitation in Pediatric Strabismus Surgery | completed | Phase 4 | 76 | Konkuk University Medical CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT00093470 | Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission | completed | Phase 3 | 144 | National Cancer Institute (NCI)NIH | 3 | Jul 14, 2026 | clinicaltrials |
| NCT01096602 | Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission | completed | Phase 2 | 63 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT02752035 | A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy | completed | Phase 3 | 183 | Astellas Pharma Global Development, Inc.INDUSTRY | 13 | Jul 14, 2026 | clinicaltrials |
| NCT02501330 | Safety And Efficacy Of Bosutinib(BLF) | completed | — | 702 | PfizerINDUSTRY | 0 | Jul 10, 2026 | clinicaltrials |
| NCT06182163 | Reduce Sedentary Time in Acute Lymphoblastic Leukemia(ReSeT in ALL) | completed | N/A | 20 | Children's Hospital Los AngelesOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT01916785 | OPTIM DASATINIB (Optimized Tyrosine Kinase Inhibitors Monotherapy)(OPTIM-DASA) | completed | Phase 2 | 289 | Versailles HospitalOTHER | 2 | Jul 6, 2026 | clinicaltrials |
| NCT02888964 | Pioglityazone and Imatinib for CML Patients(ACTIM) | completed | Phase 2 | 27 | Versailles HospitalOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT02896842 | A Prospective Randomized Phase II Study Evaluating the Monitoring of Imatinib Mesylate Plasmatic Through Level in Patients Newly Diagnosed With CP-CML(OPTIMIMATINIB) | completed | Phase 2 | 139 | Versailles HospitalOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT05230004 | Innovative Prosthetic Systems for Pediatric Limb Loss to Accommodate Growth | completed | N/A | 35 | University of PennsylvaniaOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT02719574 | Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation | completed | Phase 1 / Phase 2 | 336 | Forma Therapeutics, Inc.INDUSTRY | 9 | Jun 29, 2026 | clinicaltrials |
| NCT04168788 | Pharmacogenetic Study of Antimitotic Therapies Involved in Hepatic VOD in Children With Nephroblastoma or ALL(MVO) | completed | N/A | 85 | University Hospital, AngersOTHER_GOV | 1 | Jun 29, 2026 | clinicaltrials |
| NCT04195945 | CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients | completed | Phase 2 | 60 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT05363488 | Retrospective Observational Research Study to Describe the Real World Use of Bosutinib in a Single Centre in Scotland | completed | — | 17 | PfizerINDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT02393859 | Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL) | completed | Phase 3 | 111 | AmgenINDUSTRY | 24 | Jun 26, 2026 | clinicaltrials |
| NCT04205409 | Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies | completed | Phase 2 | 20 | University of WashingtonOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT06349239 | Oral Azacitidine Maintenance Post-CPX 351(ORAZ-351) | completed | — | 100 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT05440409 | CAR-Multicenter Analysis (CAR-MA): Retrospective Study to Characterize CAR T-cell Outcomes and Related Toxicities in Children and Young Adults With B-ALL | completed | — | 57 | National Cancer Institute (NCI)NIH | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07048730 | Gynecological Impact of Allogeneic Hematopoietic Stem Cell Transplantation in Adults(GYNEGRAFT) | completed | N/A | 51 | University Hospital, BordeauxOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT00408005 | Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma | completed | Phase 3 | 1,895 | National Cancer Institute (NCI)NIH | 5 | Jun 23, 2026 | clinicaltrials |
| NCT03568994 | Atovaquone (Mepron®) Combined With Conventional Chemotherapy for de Novo Acute Myeloid Leukemia (AML)(ATACC AML) | completed | Early Phase 1 | 26 | Baylor College of MedicineOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT04252508 | Impact of a Double-reading Animated Film (Child, Parents) in Preoperative on the Anxiety of Children Upon Arrival at the Operating Room(VERAPOP) | completed | N/A | 80 | University Hospital, BordeauxOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT00081874 | RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma | completed | Phase 1 / Phase 2 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT05654194 | Azacitidine Combined With Venetoclax and ATRA in Newly Diagnosed AML | completed | Phase 3 | 60 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT05024994 | A Study of E7820 in People With Bone Marrow (Myeloid) Cancers | completed | Phase 2 | 12 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT04965649 | Is There an Association Between Innate CD8+ T Cells and the Evolution of Tyrosine Kinase Inhibitor Resistance Mutations in Phi+ Hematological Malignancies.(TIPHI) | completed | — | 30 | Centre Hospitalier Universitaire de NīmesOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT05818644 | Hepatic Artery Stenosis and Thrombosis After Liver Transplantation in Children(HEPATIC) | completed | — | 583 | University Medical Center GroningenOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT03447808 | Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia | completed | Phase 1 | 15 | Jennifer WoyachOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07644351 | A Real-world Study of Asciminib Effectiveness in Philadelphia Positive Acute Lymphoblastic Leukemia Patients(ASCERTAIN) | completed | — | 37 | Novartis PharmaceuticalsINDUSTRY | 12 | Jun 12, 2026 | clinicaltrials |
| NCT02997761 | Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia | completed | Phase 2 | 19 | University of California, DavisOTHER | 1 | Jun 9, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Aug 3, 2026source: clinicaltrials